Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):965-973. doi: 10.2215/CJN.10941016. Epub 2017 May 26.

Abstract

Background and objectives: Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial.

Design, setting, participants, & measurements: We conducted a randomized controlled trial of prevalent hemodialysis recipients already receiving calcium carbonate as a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33-4.66 mg/dl (0.75-1.50 mmol/L) or a liberalized target of 6.20-7.75 mg/dl (2.00-2.50 mmol/L) by titrating calcium carbonate using a dosing nomogram. The primary outcome was the difference in the change in serum phosphate from randomization to 26 weeks.

Results: Fifty-three participants were randomized to the intensive group and 51 to the liberalized group. The median (interquartile range) daily dose of elemental calcium at 26 weeks was 1800 (1275-3000) mg in the intensive group, and 0 (0-500) mg in the liberalized group. The mean (SD) serum phosphate at 26 weeks was 4.53 (1.12) mg/dl (1.46 [0.36] mmol/L) in the intensive group and 6.05 (1.40) mg/dl (1.95 [0.45] mmol/L) in the liberalized group. Phosphate concentration in the intensive group declined by 1.24 (95% confidence interval, 0.75 to 1.74) mg/dl (0.40 [95% confidence interval, 0.24 to 0.56] mmol/L) compared with the liberalized group. There were no statistically significant differences between the two groups in the risk of hypercalcemia, hypocalcemia, parathyroidectomy, or major vascular events.

Conclusions: It is feasible to achieve and maintain a difference in serum phosphate concentrations in hemodialysis recipients by titrating calcium carbonate. A large trial is needed to determine if targeting a lower serum phosphate concentration improves patient-important outcomes.

Keywords: Calcium Carbonate; Calcium, Dietary; Canada; Goals; Hemodialysis; Humans; Hypercalcemia; Hypocalcemia; Kidney Failure, Chronic; Nomograms; Parathyroidectomy; Phosphates; Pilots; Prevalence; Random Allocation; hyperphosphatemia; phosphate binders; randomized controlled trials; renal dialysis; renal insufficiency, chronic.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biomarkers / blood
  • Calcium Carbonate / administration & dosage*
  • Calcium Carbonate / adverse effects
  • Canada
  • Chelating Agents / administration & dosage*
  • Chelating Agents / adverse effects
  • Drug Dosage Calculations
  • Drug Monitoring
  • Feasibility Studies
  • Female
  • Humans
  • Hyperphosphatemia / blood
  • Hyperphosphatemia / etiology
  • Hyperphosphatemia / prevention & control*
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Nomograms
  • Phosphates / blood*
  • Pilot Projects
  • Quality of Life
  • Renal Dialysis* / adverse effects
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Chelating Agents
  • Phosphates
  • Calcium Carbonate